The AiVoni Analysis Service allows users to identify heart arrhythmia anytime, anywhere. It is developed by the Finnish, Kuopio-based company Heart2Save that was founded by a group of cardiologists and other medical experts. AiVoni is the first medical application that uses the ECG feature of the Movesense sensor.
AiVoni has been certified as a medical device (CE 0537 / Class IIa), which means it has gone through the same process as devices used in hospitals, ensuring product quality and patient safety. When the user measures his/her heart, the AiVoni Analysis Service produces an ECG and analyses it in order to determine whether there is a potentially dangerous atrial fibrillation or, for example, harmless extrasystoles.
Heart2Save’s ideology is built on evidence-based medicine. Factors increasing the risk for heart diseases are, e.g. > 65 age, overweight, high blood pressure, diabetes, smoking and too little exercise. According to guidelines of the European Society of Cardiology, these risk groups are recommended to be screened for arrhythmia regularly.
The AiVoni service has been developed in cooperation with consumers in the risk groups, retirement homes, the Finnish Heart Association, cardiologists and neurologists. User-driven planning, combined with experts’ know-how, has shaped AiVoni into a unique and easy-to-use product for the ordinary consumer.
First on the market (Q2/2021) will be an ECG-necklace that will revolutionize self-monitoring of the heart rhythm. The beautiful design, combined with reliable arrhythmia analysis, enables you to monitor the well-being of your heart in a stylish, unnoticeable way – at home, at work, on holiday – no matter where you are. A handheld measuring device, suitable both for professional and consumer use, will also be introduced to the markets during 2021.